Targets › BMP7
1 program from 1 company in 1 trial: 1 Phase 4; Other; next expected readout Jan 2028.
Growth factor of the TGF-beta superfamily that plays important role in various biological processes, including embryogenesis, hematopoiesis, neurogenesis and skeletal morphogenesis. Initiates the canonical BMP signaling cascade by associating with type I receptor ACVR1 and type II receptor ACVR2A. Once all three components are bound together in a complex at the cell surface, ACVR2A phosphorylates and activates ACVR1. (UniProt, P18075)
Open in Phaseline: the race on BMP7, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The University of Texas Health Science Center, Houston | Demineralized Bone Matrix/Bone Morphogenic Protein (DBM/BMP) Bone morphogenic protein with demineralized bone matrix to promote alveolar bone formation | BMP2, BMP7 | Phase 4 | Cleft Lip and Palate | Jan 2028 |
Cleft Lip and Palate (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.